...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Urology >Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and
【24h】

Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and

机译：新辅助化疗治疗局部晚期膀胱癌中多药耐药蛋白P-糖蛋白，多药耐药蛋白1，乳腺癌耐药蛋白和肺耐药相关蛋白的表达

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: Resistance to chemotherapy is a major obstacle to overcome in the conservative treatment of patients with locally advanced bladder cancer (LABC). We investigated the predictive value of the response to neoadjuvant chemotherapy (NACT) and prognosis of the expression of multidrug resistance (MDR) related proteins, P-glycoprotein (P-gp), multidrug resistance protein 1 (MRP1), breast cancer resistance protein (BCRP) and lung resistance related protein/major vault protein (LRP/MVP) in LABC. MATERIALS AND METHODS: Using immunohistochemistry we studied the expression of MDR proteins in tumors from 83 patients with LABC treated with NACT using a bladder sparing approach. Expression was related to the response to NACT, bladder preservation and prognosis. RESULTS: P-gp, MRP1, BCRP and LRP/MVP were expressed at high levels in 53%, 59%, 28% and 70% of cases, respectively. P-gp expression correlated with shorter progression-free survival (p = 0.04) but not with overall survival. Surprisingly MRP1 expression correlated with a higher response (p = 0.005) and a higher probability of bladder preservation following NACT (p = 0.001). BCRP did not show any prognostic impact. High LRP/MVP expression was significantly associated with a worse response to NACT and a decreased probability of bladder preservation (p = 0.035). CONCLUSIONS: Our data suggest that MRP1 and LRP/MVP may be useful in combination with other clinicopathological prognostic factors for selecting patients with LABC to be candidates for bladder preservation after NACT. A large prospective study is warranted to confirm the prognostic value of these MDR proteins.
机译：目的：对局部晚期膀胱癌（LABC）患者的保守治疗中，对化疗的耐药性是克服的主要障碍。我们调查了对新辅助化疗（NACT）反应的预测价值以及多药耐药（MDR）相关蛋白，P-糖蛋白（P-gp），多药耐药蛋白1（MRP1）和乳腺癌耐药蛋白（ BCRP）和LABC中与肺阻力相关的蛋白/主要穹ault蛋白（LRP / MVP）。材料与方法：采用免疫组织化学方法，我们通过膀胱保留方法研究了83例接受NACT治疗的LABC患者的肿瘤中MDR蛋白的表达。表达与对NACT，膀胱保存和预后的反应有关。结果：P-gp，MRP1，BCRP和LRP / MVP分别高表达，分别为53％，59％，28％和70％。 P-gp表达与较短的无进展生存期相关（p = 0.04），但与总体生存期无关。出乎意料的是，MRP1表达与更高的应答率（p = 0.005）和NACT后膀胱保存的可能性更高（p = 0.001）相关。 BCRP没有显示出任何预后影响。 LRP / MVP的高表达与对NACT的反应较差以及膀胱保存的可能性降低显着相关（p = 0.035）。结论：我们的数据表明，MRP1和LRP / MVP可能与其他临床病理预后因素相结合，有助于选择LABC患者作为NACT后膀胱保存的候选者。有必要进行大规模的前瞻性研究，以证实这些MDR蛋白的预后价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号